FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1899-1912 May 5, 2005 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Psoriasis, a common inflammatory skin disorder, has received attention as a target for new pathogenesis-oriented biologic therapies. In this article, we review the genetic, clinical, and pathogenic aspects of psoriasis and discuss their implications for new therapies.

Epidemiologic and Genetic Features

Though psoriasis is a common skin disease, its definition by Ferdinand von Hebra as a distinct entity dates back only to the year 1841, and estimates of its prevalence — around 2 percent, according to standard textbooks — stem from only a few population-based studies. Perhaps the most comprehensive field study was performed in the Faroe Islands, where 2.8 percent of the inhabitants . . . [Full Text of this Article]

Clinical and Histopathological Features

Immunopathogenesis

Cytokines, Chemokines, and Adhesion Molecules

Therapy

Source Information

From the Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine, and the Department of Dermatology, University of Würzburg, Würzburg (M.P.S.); and the Department of Dermatology, University of Frankfurt, Frankfurt (W.-H.B.) — both in Germany.

Address reprint requests to Dr. Schön at the Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine and Department of Dermatology, Julius Maximilians University, Versbacher Str. 9, 97078 Würzburg, Germany, or at michael.schoen@virchow.uni-wuerzburg.de.

Related Letters:

Psoriasis
Madariaga M. G., Naldi L., Chatenoud L., Khan S., Schön M. P., Boehncke W.-H.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:848-850, Aug 25, 2005. Correspondence

This article has been cited by other articles:

• Hvid, H., Teige, I., Kvist, P. H., Svensson, L., Kemp, K. (2008). TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol 0: dxn068v1-dxn068 [Abstract] [Full Text]  
• Wang, H., Kess, D., Lindqvist, A.-K. B., Peters, T., Sindrilaru, A., Wlaschek, M., Blakytny, R., Holmdahl, R., Scharffetter-Kochanek, K. (2008). A 9-Centimorgan Interval of Chromosome 10 Controls the T Cell-Dependent Psoriasiform Skin Disease and Arthritis in a Murine Psoriasis Model. J. Immunol. 180: 5520-5529 [Abstract] [Full Text]  
• Schmuth, M., Jiang, Y. J., Dubrac, S., Elias, P. M., Feingold, K. R. (2008). Thematic Review Series: Skin Lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J. Lipid Res. 49: 499-509 [Abstract] [Full Text]  
• Arakura, F., Hida, S., Ichikawa, E., Yajima, C., Nakajima, S., Saida, T., Taki, S. (2007). Genetic Control Directed toward Spontaneous IFN-{alpha}/IFN-beta Responses and Downstream IFN-{gamma} Expression Influences the Pathogenesis of a Murine Psoriasis-Like Skin Disease. J. Immunol. 179: 3249-3257 [Abstract] [Full Text]  
• Stern, R. S. (2007). Psoralen and Ultraviolet A Light Therapy for Psoriasis. NEJM 357: 682-690 [Full Text]  
• Setty, A. R., Curhan, G., Choi, H. K. (2007). Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women: Nurses' Health Study II. Arch Intern Med 167: 1670-1675 [Abstract] [Full Text]  
• Mee, J. B., Johnson, C. M., Morar, N., Burslem, F., Groves, R. W. (2007). The Psoriatic Transcriptome Closely Resembles That Induced by Interleukin-1 in Cultured Keratinocytes: Dominance of Innate Immune Responses in Psoriasis. Am. J. Pathol. 171: 32-42 [Abstract] [Full Text]  
• Krueger, G. G., Langley, R. G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., Dooley, L. T., Lebwohl, M., the CNTO 1275 Psoriasis Study Group, (2007). A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis. NEJM 356: 580-592 [Abstract] [Full Text]  
• Chan, J. R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S., Lucian, L., Geissler, R., Brodie, S., Kimball, A. B., Gorman, D. M., Smith, K., de Waal Malefyt, R., Kastelein, R. A., McClanahan, T. K., Bowman, E. P. (2006). IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203: 2577-2587 [Abstract] [Full Text]  
• Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., Troxel, A. B. (2006). Risk of myocardial infarction in patients with psoriasis.. JAMA 296: 1735-1741 [Abstract] [Full Text]  
• Kess, D., Lindqvist, A.-K. B., Peters, T., Wang, H., Zamek, J., Nischt, R., Broman, K. W., Blakytny, R., Krieg, T., Holmdahl, R., Scharffetter-Kochanek, K. (2006). Identification of Susceptibility Loci for Skin Disease in a Murine Psoriasis Model. J. Immunol. 177: 4612-4619 [Abstract] [Full Text]  
• Paulino, L. C., Tseng, C.-H., Strober, B. E., Blaser, M. J. (2006). Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions.. J. Clin. Microbiol. 44: 2933-2941 [Abstract] [Full Text]  
• Kary, S, Worm, M, Audring, H, Huscher, D, Renelt, M, Sorensen, H, Stander, E, Maass, U, Lee, H, Sterry, W, Burmester, G-R (2006). New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor {alpha} antagonists. Ann Rheum Dis 65: 405-407 [Abstract] [Full Text]  
• Madariaga, M. G., Naldi, L., Chatenoud, L., Khan, S., Schon, M. P., Boehncke, W.-H. (2005). Psoriasis. NEJM 353: 848-850 [Full Text]